Aurinia Pharmaceuticals (AUPH) Capital Expenditures Growth (1y) (2021 - 2026)
Aurinia Pharmaceuticals (AUPH) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Aurinia Pharmaceuticals | 2.04 Bn | 1.66 Bn | 71.20 Mn | 129.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 129.41% |
| Jun 30, 2025 | -683.59% |
| Mar 31, 2025 | 41.67% |
| Dec 31, 2024 | 89.33% |
| Sep 30, 2024 | -21.90% |
| Jun 30, 2024 | -74.75% |
| Mar 31, 2024 | -29.41% |
| Dec 31, 2023 | -296.59% |
| Sep 30, 2023 | -362.50% |
| Jun 30, 2023 | 1,200.00% |
| Mar 31, 2023 | -78.48% |
| Dec 31, 2022 | 113.22% |
| Sep 30, 2022 | -98.86% |
| Jun 30, 2022 | -98.89% |
| Mar 31, 2022 | 134.50% |
| Dec 31, 2021 | 62.12% |
| Sep 30, 2021 | -5.91% |
| Jun 30, 2021 | 1,082.43% |
| Mar 31, 2021 | -389.87% |